NDA 014399 · Validus Pharms
Norpramin
Desipramine Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1964
Nov 20, 1964
Approved uses
2
Original approval plus efficacy supplements
Registered trials
39
6 Phase 3, 0 recruiting
FAERS reports
279
185 serious, 27 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studiesof major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of NORPRAMIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely...
What it is approved for
From the label in effect Jul 3, 2025.
INDICATIONS AND USAGE NORPRAMIN is indicated for the treatment of depression.
Mechanism: Mechanism of Action Available evidence suggests that many depressions have a biochemical basis in the form of a relative deficiency of neurotransmitters such as norepinephrine and serotonin. Norepinephrine deficiency may be associated with relatively low urinary 3-methoxy-4-hydroxyphenyl glycol (MHPG) levels, while serotonin deficiencies may be associated with low spinal fluid levels of 5-hydroxyindoleacetic acid. While the precise mechanism of action of the tricyclic antidepressants is unknown, a leading theory suggests that they restore normal levels of neurotransmitters by blocking the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 25, 1976 Supplement 20 · Efficacy
- Nov 20, 1964 Original approval · Type 2 - New Active Ingredient Other Important Information from FDA
6 products under this application
- NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 10MG · TABLET, ORAL · Discontinued · TE AB
- NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 100MG · TABLET, ORAL · Discontinued · TE AB
- NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 50MG · TABLET, ORAL · Discontinued · TE AB
- NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 25MG · TABLET, ORAL · Discontinued · TE AB
- NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 150MG · TABLET, ORAL · Discontinued · TE AB
- NORPRAMIN · DESIPRAMINE HYDROCHLORIDE 75MG · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Desipramine" as an intervention, any sponsor and status, largest first.
- Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research GroupPivotal-lookingCompleted
National Institute of General Medical Sciences (NIGMS)NIH
NCT00265291 · 700 participants · Start Nov 1999 · Primary completion May 2006
Drug: fluoxetine or desipramine · For: Major Depressive Disorder; Major Depression; Unipolar Depression
Sites: Miami, Florida
- A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump InhibitorsPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01265550 · 366 participants · Start Aug 13, 2012 · Primary completion Dec 30, 2016
Drug: baclofen; Desipramine · For: GERD
Sites: Birmingham, Alabama; Tucson, Arizona; Loma Linda, California · 15 sites in all
- Treatment of Functional Bowel DisordersPivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00006157 · 300 participants · Start Jul 1996
Drug: Desipramine · For: Irritable Bowel Syndrome; Constipation; Abdominal Pain and 1 more
Sites: Chapel Hill, North Carolina; Toronto, Canada
- Efficacy of Antidepressants in Chronic Back PainPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT00964886 · 142 participants · Start Jan 2010 · Primary completion Dec 2014
Drug: desipramine hydrochloride; benztropine mesylate 0.125 mg daily and 1 more · For: Back Pain
Sites: San Diego, California
- Effect of Antidepressants on Back PainPivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00018200 · 130 participants · Start Apr 1999 · Primary completion Dec 2003
Drug: Desipramine; Fluoxetine and 1 more · For: Back Pain; Sciatica
Sites: San Diego, California
- Vulvar Vestibulitis Clinical Trial: Desipramine-LidocainePivotal-lookingCompleted
University of RochesterAcademic, hospital or other
NCT00276068 · 128 participants (planned) · Start Aug 2002
Drug: topical lidocaine + oral desipramine, and/or placebo · For: Vulvar Disease
Sites: Rochester, New York
- Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic NeuralgiaPivotal-lookingCompleted
National Center for Research Resources (NCRR)NIH
NCT00004390 · 120 participants · Start Feb 1995
Drug: desipramine; methadone and 2 more · For: Pain; Herpes Zoster
- New Approaches to Cocaine Abuse Medications (A) - 6Pivotal-lookingCompleted
New York State Psychiatric InstituteAcademic, hospital or other
NCT00000271 · 111 participants · Start Jan 1995 · Primary completion Oct 2002
Drug: Desipramine; Placebo · For: Cocaine-Related Disorders; Substance-Related Disorders
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective29
- fatigue22
- drug hypersensitivity17
- nausea17
- headache16
- dyspnoea15
- toxicity to various agents15
- off label use14
- confusional state13
- dizziness12
- vomiting12
- depression11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 11 |
| 2006 | 9 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 8 |
| 2010 | 12 |
| 2011 | 18 |
| 2012 | 16 |
| 2013 | 6 |
| 2014 | 11 |
| 2015 | 15 |
| 2016 | 17 |
| 2017 | 22 |
| 2018 | 16 |
| 2019 | 15 |
| 2020 | 12 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 10 |
| 2024 | 15 |
| 2025 | 20 |
| 2026 | 15 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis.
Zhou X, Teng T, Zhang Y, et al. · Lancet Psychiatry 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Nocturnal enuresis.
Kiddoo D · BMJ Clin Evid 2011 · Systematic Review
- Cognitive therapy vs medications in the treatment of moderate to severe depression.
DeRubeis RJ, Hollon SD, Amsterdam JD, et al. · Arch Gen Psychiatry 2005 · Clinical Trial, Comparative Study
- Nocturnal enuresis.
Kiddoo D · BMJ Clin Evid 2007 · Systematic Review
- Pharmacotherapy for trichotillomania.
Hoffman J, Williams T, Rothbart R, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Validus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.